PPA
ANIP icon

Parametric Portfolio Associates’s ANI Pharmaceuticals ANIP Stock Holding History

Parametric Portfolio Associates’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$1.13M Buy
40,228
+5,464
+16% +$204K ﹤0.01% 2724
2021
Q4 		$1.6M Buy
34,764
+9,398
+37% +$404K ﹤0.01% 2575
2021
Q3 		$833K Sell
25,366
-3,543
-12% -$110K ﹤0.01% 2882
2021
Q2 		$1.01M Buy
28,909
+9,924
+52% +$338K ﹤0.01% 2768
2021
Q1 		$686K Buy
18,985
+1,064
+6% +$33.3K ﹤0.01% 3337
2020
Q4 		$520K Sell
17,921
-17,684
-50% -$506K ﹤0.01% 3365
2020
Q3 		$1M Buy
35,605
+3,474
+11% +$103K ﹤0.01% 2917
2020
Q2 		$1.04M Buy
32,131
+14,657
+84% +$526K ﹤0.01% 2904
2020
Q1 		$712K Sell
17,474
-8,605
-33% -$458K ﹤0.01% 2978
2019
Q4 		$1.61M Sell
26,079
-4,185
-14% -$277K ﹤0.01% 2827
2019
Q3 		$2.21M Sell
30,264
-1,793
-6% -$134K ﹤0.01% 2577
2019
Q2 		$2.63M Buy
32,057
+6,802
+27% +$484K ﹤0.01% 2479
2019
Q1 		$1.78M Buy
25,255
+2,070
+9% +$122K ﹤0.01% 2722
2018
Q4 		$1.04M Buy
23,185
+2,541
+12% +$133K ﹤0.01% 2959
2018
Q3 		$1.17M Sell
20,644
-992
-5% -$60.7K ﹤0.01% 3006
2018
Q2 		$1.45M Buy
21,636
+1,948
+10% +$122K ﹤0.01% 2863
2018
Q1 		$1.15M Buy
19,688
+4,328
+28% +$275K ﹤0.01% 2944
2017
Q4 		$990K Sell
15,360
-408
-3% -$25.4K ﹤0.01% 3025
2017
Q3 		$828K Buy
15,768
+798
+5% +$38.1K ﹤0.01% 3145
2017
Q2 		$701K Buy
14,970
+3,133
+26% +$151K ﹤0.01% 3178
2017
Q1 		$586K Sell
11,837
-829
-7% -$46.5K ﹤0.01% 3121
2016
Q4 		$768K Buy
12,666
+1,010
+9% +$61.8K ﹤0.01% 2977
2016
Q3 		$773K Buy
11,656
+3,240
+38% +$203K ﹤0.01% 2948
2016
Q2 		$470K Buy
8,416
+291
+4% +$14.1K ﹤0.01% 3232
2016
Q1 		$273K Buy
+8,125
New +$276K ﹤0.01% 3639
2015
Q3 		– Sell
-7,113
Closed -$441K – 3266
2015
Q2 		$441K Sell
7,113
-8,972
-56% -$534K ﹤0.01% 3351
2015
Q1 		$1.01M Sell
16,085
-1,880
-10% -$114K ﹤0.01% 2782
2014
Q4 		$1.01M Buy
17,965
+4,050
+29% +$179K ﹤0.01% 2776
2014
Q3 		$394K Buy
13,915
+1,687
+14% +$50.6K ﹤0.01% 3343
2014
Q2 		$421K Buy
12,228
+441
+4% +$13.8K ﹤0.01% 3310
2014
Q1 		$370K Buy
+11,787
New +$313K ﹤0.01% 3341

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Parametric Portfolio Associates's ANIP Position: Q1 2022 in Review

Parametric Portfolio Associates increased its ANI Pharmaceuticals (ANIP) stake by 16% in Q1 2022, buying an estimated $204K and bringing the position to 40,228 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2724.

Parametric Portfolio Associates first reported a position in ANIP in Q1 2014 and has held it in 31 quarters since. The position peaked at $2.63M in Q2 2019. 126 funds tracked by Wall St. Rank hold ANIP as of Q1 2022.

  • Parametric Portfolio Associates held 40,228 shares of ANI Pharmaceuticals worth $1.13M as of Q1 2022.
  • Parametric Portfolio Associates bought 5,464 ANI Pharmaceuticals shares in Q1 2022, an estimated $204K.
  • ANI Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2724 holding.
  • Parametric Portfolio Associates first reported a position in ANI Pharmaceuticals in Q1 2014 and has held it in 31 quarters since.
  • Parametric Portfolio Associates's ANI Pharmaceuticals position peaked at $2.63M in Q2 2019.
  • 126 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.